Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NRG1
UPID:
PRDC1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NRG1; B7Z1Z3; Q53HA7; Q59EL9; Q5VV18; Q5VV20
Background:
Phosphoribosyltransferase domain-containing protein 1, identified by the accession number Q9NRG1, exhibits minimal phosphoribosyltransferase activity in vitro. It has the capability to bind molecules such as GMP, IMP, and alpha-D-5-phosphoribosyl 1-pyrophosphate (PRPP), indicating a specific, albeit limited, role in cellular processes. Despite its low activity, the protein's interaction with these molecules suggests a nuanced function within the cell, potentially related to purine metabolism or GMP salvage pathways.
Therapeutic significance:
Understanding the role of Phosphoribosyltransferase domain-containing protein 1 could open doors to potential therapeutic strategies. Its unique interactions and activity profile make it a candidate for further investigation in the context of drug discovery, aiming to elucidate its potential impact on disease mechanisms and treatment options.